These are the stocks posting the largest moves before the bell.Market Insiderread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
Alphabet Inc's Google said Tuesday that keeping phones up to date and secure was in "everyone's best interests," shortly after the U.S. temporarily eased some trade...Technologyread more
Technology stocks are a casualty of the trade war, but analysts say there's a chance longer term some companies might emerge stronger, depending on what kind of deal is...Market Insiderread more
Home Depot on Tuesday reported fiscal first-quarter earnings that beat analysts expectations, despite a damp start to the spring in much of the U.S.Retailread more
As tariff worries hit Apple, the stock has fallen into a bear market. But Joule Financial's Quint Tatro believes the pullback represents a buying opportunity, while...Trading Nationread more
American Airlines slashed fees for surf boards, skis and other oversize sports equipment as well as music gear. Rival United Airlines last year took a similar step cutting...Airlinesread more
Shares of chipmakers rebounded from a sell-off on Tuesday after the U.S. temporarily eased some trade restrictions on China's Huawei.Marketsread more
Stocks are weathering the latest bouts increasing trade fears, but the bond market is pointing to more trouble ahead.Marketsread more
June marks the start of Atlantic hurricane season, and after years of record damage from increasingly powerful storms, homeowners and builders are looking intensely at ways to...Rising Risksread more
Indian billionaire investor Rakesh Jhunjhunwala says he's very upbeat about his country's growth potential after the country underwent a massive banking crisis and the rollout...Asia Economyread more
WEST LAFAYETTE, Ind., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 11, at 3:05 p.m. EDT. The conference will be held at the Le Parker Meridien Hotel in New York.
A live audio webcast of the Company's presentation can be accessed at http://wsw.com/webcast/wedbush30/ecyt or by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, firstname.lastname@example.org